PARIS, FRANCE, 1 September 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global
specialty-driven biopharmaceutical company, announced today the appointment of
Christelle Huguet as Executive Vice President, Head of Research and Development.
She will succeed Howard Mayer, EVP and Head of R&D, who will leave Ipsen on
September 22, following his decision to retire.
Christelle Huguet will serve on the Executive Leadership Team (ELT), reporting
directly to Ipsen's Chief Executive Officer, David Loew and immediately
succeeding Howard upon his departure. Since joining Ipsen in May 2020 as Senior
Vice President and Head of Research, External Innovation and Early Development
(REED), she has built a lean and dynamic global REED organization supporting
Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience, from
target to clinic.
"I am very pleased that Christelle will join Ipsen's Executive Leadership team
as we continue to successfully deliver on our strategic roadmap. Christelle's
deep experience, spanning discovery and development, will be essential to
advance our pipeline and drive positive developments from external innovation.
This experience, coupled with her passion and leadership style of developing
people, will ensure a smooth transition as she assumes her new role," said David
Loew, CEO, Ipsen.
"I also want to thank Howard for his significant contributions to Ipsen. Over
the last four years he built a strong R&D leadership team, which led a deep
review of the pipeline, prioritized disease areas, and identified strategic
programs and opportunities. Howard was also instrumental in Ipsen's success from
a Business Development and M&A perspective over the last several years, and he
played a pivotal role in the acquisitions and integrations of Epizyme and
Albireo into Ipsen. He has remained personally committed to bringing much-needed
innovation to patients throughout his distinguished career."
Christelle brings depth and expertise, with over 25 years of biotech and
industry experience spanning drug discovery and development from the early
phases of drug discovery to the identification and early clinical development of
small molecules and biologics up to Phase IIb. Prior to joining Ipsen in,
Christelle was Chief Scientific Officer for X-Chem Inc & ZebiAI Therapeutics,
where she built an internal portfolio of oncology programs and implemented the
use of advanced machine learning to DNA-encoded library data analysis. Prior to
X-Chem, she was the head of internal research at Alexion, where she focused on
rare diseases. Earlier in her career, she spent 18 years at Pfizer in a number
of senior leadership roles in research and pre-clinical development, including
CSO for GU disease, Global Head of PK, PD and Metabolism, and CSO for
inflammation and immunology.
"I know firsthand that our R&D organization is committed to Ipsen's ambitious
innovation agenda," said Christelle Huguet. "I'm honored to lead this talented
team to continue to bring much-needed new medicines in Oncology, Rare Disease
and Neuroscience, where we can make a meaningful impact for patients and
society."
Christelle studied in France, Germany and Switzerland, receiving a French
University Diploma in Technology (DUT) in applied biology and biochemistry, and
a European Engineering degree in biotechnology sciences. She received a Ph.D. in
molecular and cellular biology from the Institute Pasteur in France. Christelle
will continue to be based in Cambridge, Massachusetts, one of Ipsen's four
global hubs, and will assume her new role from 22 September 2023.
ENDS
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative
medicines in Oncology, Rare Disease and Neuroscience. With total sales of EUR3.0bn
in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-
innovation strategy, the Company's research and development efforts are focused
on its innovative and differentiated technological platforms located in the
heart of leading biotechnological and life-science hubs: Paris-Saclay, France;
Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300
colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S.
through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
For more information, visit ipsen.com (https://www.ipsen.com)
For further information:
Contacts
Investors
Craig Marks Nicolas Bogler
Vice President, Investor Relations Senior Manager, Investor Relations
+44 (0)7584 349 193 +33 6 52 19 98 92
Media
Amy Wolf Ioana Piscociu
VP, Head of Corporate Brand Strategy Senior Manager
& Communications Global Media Relations
+41 79 576 07 23 +33 6 69 09 12 96
Ipsen's forward-looking statements
The forward-looking statements, objectives and targets contained herein are
based on Ipsen's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen's future ability
to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words 'believes', 'anticipates' and 'expects' and similar expressions are
intended to identify forward-looking statements, including Ipsen's expectations
regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking
into account external-growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend on conditions
or facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. Ipsen must face or might face competition from generic
medicine that might translate into a loss of market share. Furthermore, the
research and development process involves several stages each of which involves
the substantial risk that Ipsen may fail to achieve its objectives and be forced
to abandon its efforts with regards to a medicine in which it has invested
significant sums. Therefore, Ipsen cannot be certain that favorable results
obtained during preclinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can
be no guarantees a medicine will receive the necessary regulatory approvals or
that the medicine will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation; global trends
toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Ipsen's patents and other protections for
innovative medicines; and the exposure to litigation, including patent
litigation, and/or regulatory actions. Ipsen also depends on third parties to
develop and market some of its medicines which could potentially generate
substantial royalties; these partners could behave in such ways which could
cause damage to Ipsen's activities and financial results. Ipsen cannot be
certain that its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of Ipsen's partners
could generate lower revenues than expected. Such situations could have a
negative impact on Ipsen's business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this press release
to reflect any change in events, conditions, assumptions or circumstances on
which any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen's latest Universal Registration Document, available on ipsen.com
(https://www.ipsen.com).
Â